People suffering with neurological diseases are at risk of committing suicide. A case-control study found increased risk of attempted suicide in patients with nine chronic neurological diseases [1]

We recently reviewed the scientific literature linking dopamine agonist pharmacotherapy for neurological disorders to the development of impulsive and compulsive spectrum disorders (ICSDs). 

This article delves into the groundbreaking applications of artificial intelligence (AI) in psychiatry, revolutionizing the field and improving patient care. AI technologies have shown immense potential in augmenting diagnostic accuracy, predicting treatment outcomes, and facilitating personalized therapeutic interventions. This article reviews the latest advancements and discusses the ethical considerations associated with AI integration in psychiatric practice.

Autoantibodies are antibodies produced by B cells capable of attacking their own tissues or organs after loss of immune tolerance. A large body of literature shows that autoantibodies play an important role in neurological diseases associated with immune abnormalities. Nowadays, neurological disorders are an important cause of disability and death in populations around the world, so it is important to study the role and mechanisms of autoantibodies in neurological disorders associated with immune abnormalities.

This essay discusses a shift in the priorities in the psychiatric community over the past several decades from one that focuses upon the relief of suffering toward one that emphasizes harm reduction and danger prevention. The essay reviews the various forces that have driven this evolution including legal decisions that have limited grounds for admission to dangerousness, models of care that emphasize “zero suicide,” a rise in liability for outpatient suicide and the resulting practice of defensive medicine.